About ISPE > News Releases > ISPE Names New 2007-2008 Chair

ISPE NEWS
FOR IMMEDIATE RELEASE

For more information contact:
Marni Schribman
Communications Manager
Tel: 1-813/960-2105
E-mail: mailto:mschribman@ispe.org
www.ispe.org

ISPE Names AstraZeneca’s Bruce Davis as New 2007-2008 Chair

(TAMPA, FLORIDA, USA, 6 DECEMBER 2007) – ISPE, a global not-for-profit association of 25,000 pharmaceutical manufacturing professionals, has elected Bruce S. Davis as Chair of its International Board of Directors for the 2007-2008 year.

Davis, who served as the Board’s Vice Chair last year, works for AstraZeneca and is based in Cheshire, England. His manages various business projects including those for Quality by Design, and has an external role which also embraces his commitment to ISPE.

As a Member of ISPE since 1991, Davis is one of the Task Team Leaders for Product Quality Lifecycle Implementation (PQLI) and is a member of the PQLI Steering Committee, working to develop the initiative for the industry. He has also chaired the ISPE Technical Documents Committee and is now a member of the Technical Documents Executive Committee. He chaired the Task Team that wrote the ISPE Baseline® Guide on Sterile Manufacturing Facilities, and also is chairing the team that is currently updating this Guide.

“Bruce will bring leadership in the PQLI arena, but also to many of the goals the Society has to shape the industry,” said Robert P. Best, CEO and President of ISPE. “His expertise in the international arena – along with his technical knowledge on guidances and practical solutions, will ensure he will be a strong asset to ISPE,” said Best.

Davis has given many presentations and organized educational events for ISPE in the USA, Europe, and Australia. Regarding other organizations, he also is secretary to the ASTM E55.03 Committee.

“ISPE’s volunteer status, our international presence, and our links to the regulators enable ISPE to take a lead in providing the training and education that our industry wants – be it international events, local seminars, or publications,” said Davis. “I will support the ever strengthening links between science and engineering and will encourage greater understanding and communication internationally.

“I will encourage ISPE to provide the tools and training that are needed to support the industry’s professionals – whether individuals are from large or small companies, from small or large molecule background, from generics or new products, from manufacturing companies, suppliers, agencies or academia, or from different countries around the globe.”

Davis is a professional engineer, and he has worked in a range of other businesses, mainly in the engineering field, where he was responsible for new formulation assets internationally. He has wide international knowledge and has been involved in sterile, oral solid dosage, packaging, and bulk plants and laboratories in many countries in the continents of North America, Europe, Asia, and Australasia.

About ISPE
ISPE, the International Society for Pharmaceutical Engineering, is the Society of choice for 25,000 pharmaceutical manufacturing professionals in 90 countries around the globe. ISPE aims to be the catalyst for "Engineering Pharmaceutical Innovation" by providing Members with opportunities to develop technical knowledge, exchange practical experience, and collaborate with global regulatory agencies and industry leaders. Founded in 1980, ISPE has worldwide headquarters in Tampa, Florida, USA; its European office in Brussels, Belgium; and its Asia Pacific office in Singapore. Visit www.ISPE.org for additional Society news and information.